Difference between revisions of "Clarithromycin (Biaxin)"
Jump to navigation
Jump to search
m |
m |
||
(One intermediate revision by the same user not shown) | |||
Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
− | *[[ | + | *[[Diffuse large B-cell lymphoma]] |
+ | *[[B-cell lymphoma of mucosa-associated lymphoid tissue]] | ||
+ | |||
+ | ==Diseases for which it was used== | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
Line 13: | Line 16: | ||
[[Category:Antibacterials]] | [[Category:Antibacterials]] | ||
− | [[Category: | + | [[Category:Diffuse large B-cell lymphoma medications]] |
− | [[Category:Multiple myeloma medications]] | + | [[Category:MALT lymphoma medications]] |
+ | [[Category:Multiple myeloma medications (historic)]] | ||
[[Category:FDA approved in 1991]] | [[Category:FDA approved in 1991]] |
Latest revision as of 19:05, 25 April 2022
Mechanism of action
Antibiotic which inhibits bacterial protein synthesis through binding to the 50S subunit. Mechanism for observed antineoplastic effect may be through suppression of IL-6.
Diseases for which it is used
Diseases for which it was used
Also known as
- Brand name: Biaxin